For example, a therapy likely to promote activation of the LINE-1 promoter driving LCT13 or that intragenic to cMET could increase the risk of developing cancer by promoting silencing of the metastasis suppressor gene TFPI-2 or expression of the oncogenic isoform L1-MET.37,38. This evidence concerns the gene TFPI2 and cancer.